The advent of genome-wide analyses using next-generation sequencing technologies have demonstrated the landscape of molecular mutations and identified several driver genetic alterations in bile duct cancer; for example, intracholangiocarcinoma have the highest of mutations in isocitrate dehydrogenase 1 (IDH1), and fibroblast growth factor receptor (FGFR) fusions which are of special interest, because they are not detectable in other liver malignancies, whereas the most prominent mutated gene extracholangiocarcinoma is BRAF (21). This evidence concerns the gene IDH1 and bile duct cancer.